Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$76.94 USD
+1.00 (1.32%)
Updated May 7, 2024 04:00 PM ET
After-Market: $76.95 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
Axsome Therapeutics, Inc. [AXSM]
Reports for Purchase
Showing records 1 - 20 ( 174 total )
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Solriamfetol ENGAGE Phase 3 Trial Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AXS-12 SYMPHONY Phase 3 Trial Yields Positive Data; Raising PT to $190
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Solriamfetol PARADIGM Phase 3 Trial Starts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Path to Profitability; 2023 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary 4Q23 Revenue Numbers Beat Expectations; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Karuna Acquisition Deal Bodes Well for Axsome; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department